US equities |
NVDA $186.64 ▲+2.78% MU $690.00 ▲+5.12% AMD $449.04 ▲+11.04% SPCX $134.27 ▲+8.62% AAPL $342.37 ▼-0.52% SNDK $835.06 ▲+3.55% MSFT $530.61 ▼-0.99% TSLA $358.22 ▲+4.23%
FinancialContent

CorMedix Inc. - Common Stock (NQ:CRMD)

5.320 +0.090 (+1.72%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CorMedix Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
CorMedix (CRMD) Q2 2026 Earnings Call Transcript ↗
DefenCath revenue hit $66.1M as CorMedix expands dialysis partnerships and advances REZZAYO. 
Via The Motley Fool
Topics Earnings
News headline image
CorMedix Q2 Earnings Call Highlights ↗
CorMedix (NASDAQ:CRMD) reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted... 
Via MarketBeat
Topics Earnings
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
CorMedix Inc (NASDAQ:CRMD) Surges After Blowout Q1 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
CorMedix Inc (NASDAQ:CRMD) Shares Drop on Q4 2025 Earnings Miss ↗
Via Chartmill
CorMedix Inc (NASDAQ:CRMD) Exemplifies a High-Growth Stock Screen Methodology ↗
Via Chartmill
CorMedix Stock Breaks Out To 2-Month High: Analysts Reset Price Targets After Blowout Q3 And Surging DefenCath Demand ↗
Via Stocktwits
News headline image
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms ↗
CorMedix (NASDAQ:CRMD) CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible... 
Via MarketBeat
News headline image
CorMedix (CRMD) Q1 2026 Earnings Transcript ↗
CorMedix (CRMD) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
CorMedix Q1 Earnings Call Highlights ↗
CorMedix (NASDAQ:CRMD) reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while... 
Via MarketBeat
Topics Earnings
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
CorMedix (CRMD) Q4 2025 Earnings Call Transcript ↗
CorMedix (CRMD) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Why Did CRMD Stock Tumble Over 11% Today? ↗
The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 ↗
Via MarketBeat
Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD, GLUE Are On Traders' Radar Today ↗
Via Stocktwits
Topics Government Stocks
News headline image
CorMedix Stock Rises After-Hours: CEO Locks In Chairman Seat, Bigger Paycheck And Rich Severance ↗
Joseph Todisco’s annual base salary increases to $750,000 from $665,000, effective Jan. 1. 
Via Stocktwits
Here are the top movers in Thursday's session. ↗
Via Chartmill
News headline image
Why Did CRMD Stock Crash 28% Today? ↗
CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data. 
Via Stocktwits
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
CorMedix Inc (NASDAQ:CRMD): A Textbook Fit for a High-Growth Stock Screener ↗
CorMedix (CRMD) exemplifies a high-growth stock with explosive sales, strong earnings momentum, and robust profitability, fitting a proven investment framework. 
Via Chartmill
News headline image
Why CorMedix Could be the Biopharma Name to Watch Early in 2026 ↗
Via MarketBeat
News headline image
MarketBeat’s Top 5 Rated Small-Cap Stocks ↗
Via MarketBeat
News headline image
Why Is CorMedix Stock Rising Today? ↗
CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study. 
Via Stocktwits
News headline image
CorMedix Inc (NASDAQ:CRMD) Shows Explosive Growth Metrics in "Little Book" Screen ↗
CorMedix (CRMD) shows explosive sales & earnings growth, strong momentum, and a surprisingly low valuation, making it a top growth stock candidate. 
Via Chartmill
News headline image
Talphera (TLPH) Q3 2025 Earnings Call Transcript ↗
Talphera (TLPH) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations ↗
CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melinta integration progress. 
Via Benzinga
News headline image
Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance ↗
The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million. 
Via Stocktwits
Topics Earnings
News headline image
CorMedix Inc. (NASDAQ:CRMD) Q3 2025 Earnings: Revenue Beat Offsets EPS Miss ↗
CorMedix Inc. (CRMD) Q3 2025 earnings show a revenue beat of $104.3M, but an EPS miss. The stock rose in pre-market trading on strong sales growth. 
Via Chartmill
News headline image
CorMedix Inc (NASDAQ:CRMD) Fulfills Key Growth Stock Criteria from The Little Book ↗
CorMedix (CRMD) excels in a proven growth stock strategy, showing massive sales growth, strong earnings momentum, and solid profitability metrics. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >